Skip to content

Whole-Neck Computed Tomography Perfusion Scan in Imaging Patients With Head and Neck Tumors

A Pilot Study of Whole-Neck CT Perfusion With the Toshiba Aquilion ONE ViSION-320 Detector Row CT Scanner for Use in Head &Amp; Neck Tumor Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02960308
Enrollment
49
Registered
2016-11-09
Start date
2016-10-20
Completion date
2021-06-14
Last updated
2023-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Neoplasm, Malignant Head and Neck Neoplasm

Brief summary

This pilot clinical trial studies how well whole-neck computed tomography perfusion scans work in imaging patients with head and neck tumors. Diagnostic imaging procedures, such as whole-neck computed tomography perfusions scans, may provide more information about the blood supply to head and neck tumors which may help doctors plan better treatment.

Detailed description

PRIMARY OBJECTIVES: I. To assess the difference in whole-neck computed tomography perfusion (WNCTP) parameters (blood volume \[BV\], blood flow \[BF\], capillary permeability \[CP\] and mean transit time \[MTT\]) between head and neck tumor masses (benign or malignant) and adjacent normal skeletal muscle within the same patient. II. To assess whether the difference in WNCTP parameters between tumor masses and adjacent normal skeletal muscle is different between patients with benign tumor versus (vs.) malignant tumor. III. To assess the correlation in WNCTP parameters between tumor masses and adjacent normal skeletal muscle. IV. Determine if more suspicious cervical lymph nodes will be seen using the whole-neck coverage employed in WNCTP compared to the limited coverage of traditional neck CTP. OUTLINE: Patients undergo WNCTP scan over 2-3 minutes during standard of care computed tomography (CT). After completion of study, patients are followed up within 2 days.

Interventions

Undergo WNCTP scan

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
University of Southern California
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Confirmed or suspected head and neck tumor (benign or malignant) * Scheduled for contrast CT (standard of care) * No known allergies to contrast material

Exclusion criteria

* Known allergies to contrast material * Pregnant or nursing

Design outcomes

Primary

MeasureTime frameDescription
Number and site of each suspicious lymph node assessed by WNCTPDay 1Will be compared to traditional neck CTP. Within each patient, the number and sites of each suspicious lymph node will be recorded for the whole-neck imaging area. A 95% confidence interval for the proportion of patients whose status (lymph node negative \[LN-\] versus lymph node positive \[LN+\]) was changed based on the WNCTP image compared to standard of care will be constructed.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026